Pegylated-interferon (IFN) plus ribavirin remains the most effective
therapeutic regimen for patients with chronic hepatitis C interferon.
Thrombocytopenia is a common side effect of this treatment, often leading to
discontinuation of a potentially curative therapy. Splenectomy was a clinically
effective treatment for hepatitis C virus-associated thrombocytopenia.
Splenectomy in patients with hepatitis C cirrhosis is now safer prelude to
antiviral treatment. Overwhelming post splenectomy infection (OPSI) syndrome is
a rare condition, but is associated with high mortality. However, recognition
and clinical management of OPSI is not well established. We reviewed the
literature characterizing the clinicopathological features of OPSI and assessed
the most effective and feasible administration of the condition. Prevention
strategies such as vaccination and education are also potentially important
parts of the strategy for splenectomized HCV patients.
References
[1]
Anonymous (1999) Hepatitis C-Global Prevalence (Update). World Health Organization Weekly Epidemiological
Record, 74, 425-427.
[2]
McHutchison, J.G.,
Goodman, Z.D.,
Ling, M.H., et al. (1998) Interferon Alfa-2b Alone or in Combination with
Ribavirin as Initial Treatment for Chronic Hepatitis C. Hepatitis
Interventional Therapy Group. The New England
Journal of Medicine, 339, 1485-1492. http://dx.doi.org/10.1056/NEJM199811193392101
[3]
Youngster, S.,
Wang, Y.S.,
Grace, M., et al. (2002) Structure, Biology and Therapeutic Implications
of Pegylated Interferon Alpha-2b. Current
Pharmaceutical Design, 8, 2139-2157. http://dx.doi.org/10.2174/1381612023393242
[4]
Fried, M.W.,
Shiffman, M.L.,
Reddy, K.R., et al. (2002) Peginterferon Alfa-2a plus Ribavirin for Chronic
Hepatitis C Virus Infection. The New
England Journal of Medicine, 347, 975-982. http://dx.doi.org/10.1056/NEJMoa020047
[5]
McHutchison, J.G., Manns, M., Patel, K., et al. (2002) Adherence to Combination Therapy Enhances
Sustained Response in Genotype-1-Infected Patients with Chronic Hepatitis C. Gastroenterology, 123, 1061-1069. http://dx.doi.org/10.1053/gast.2002.35950
[6]
Kamal, S.M.,
EI Kamary, S.S.,
Shardel, M.D., et al. (2007) Pegylated Interferon Alpha-2b plus Ribavirin in Patients with Genotype 4
Chronic Hepatitis C: The Role of Rapid and Early Virologic Response. Hepatology, 46, 1732-1740. http://dx.doi.org/10.1002/hep.21917
Hayashi, P.H.,
Mehia, C.,
Joachim Reimers, H., et al. (2006) Splenectomy for Thrombocytopenia in Patients with
Hepatitis C Cirrhosis. Journal of Clinical
Gastroenterology, 40, 740-744. http://dx.doi.org/10.1097/00004836-200609000-00015
Martin, T.G. and Shuman, M.A. (1998) Interferon-Induced Thrombocytopenia; It Is Time for Thrombopoietin. Hepatology, 28, 1430-1432. http://dx.doi.org/10.1002/hep.510280536
Moges, M.F.,
Spigos, D.G.,
Pollak, R., Abejo, R.,
Pavel, D.G.,
Tan, W.S. and Jonasson, O. (1984) Partial Splenic Embolization, an Alternative to
Splenectomy—Results of a Prospective, Randomized Study. Surgery, 96, 694-702.
[13]
Palsson, B.
and Verbaan, H. (2005) Partial Splenic Embolization as Pretreatment for
Antiviral Therapy in Hepatitis C Virus Infection. European Journal of Gastroenterology & Hepatology, 17, 1157-1164.
[14]
Kercher, K.W.,
Carbonell, A.M., Heniford, B.T., Matthews, B.D., Cunningham, D.M. and Reindollar,
R.W. (2004) La- paroscopic Splenectomy Reverses Thrombocytopenia
in Patients with Hepatitis C Cirrhosis and Portal Hypertension. Journal of Gastrointestinal Surgery, 8, 120-126. http://dx.doi.org/10.1016/j.gassur.2003.10.009
[15]
King, H.,
Shumacker Jr., H.B. (1952)
Splenic Studies: I. Susceptibility
to Infection after Splenectomy Performed Infancy. Annals of Surgery, 136, 239-242. http://dx.doi.org/10.1097/00000658-195208000-00006
[16]
Evans, D.I. (1985)
Postsplenectomy Sepsis 10 Years or More after Operation. Journal of Clinical Pathology, 38, 309- 311. http://dx.doi.org/10.1136/jcp.38.3.309
[17]
Cullingford, G.L.,
Watkins, D.N.,
Watts, A.D. and Mallon, D.F. (1991) Severe Late
Postsplenectomy Infection. British
Journal of Surgery, 78, 716-721. http://dx.doi.org/10.1002/bjs.1800780626
[18]
Jockovich, M.,
Mendenhall, N.P.,
Somebeck, M.D., Talbert,
J.L.,
Copeland III, E.M. and Bland, K.I. (1994) Long- Term Complications of Laparotomy in Hodgkin’s Disease. Annals of Surgery, 219, 615-621. http://dx.doi.org/10.1097/00000658-199406000-00004
[19]
Landgren, O.,
Bjorkholm, M.,
konradsen, H.B., Soderqvist, M., Nilsson, B. and Gustavsson, A. (2004) A Prospective Study on Antibody Response to Repeated
Vaccinations with
Pneumococcal Capsular
Polysaccharide in Splentomized Individuals with Special Reference to Hodgkin’s Lymphoma. Journal of Internal Medicine, 255, 664-673. http://dx.doi.org/10.1111/j.1365-2796.2004.01312.x
White, K.S., Covington, D.,
Churchill, P., Maxwell,
J.G.,
Norman, K.S. and Clancy, T.V. (1991) Patient Awareness of Health Precautions after Splenectomy. American Journal of Infection Control, 19, 36-41. http://dx.doi.org/10.1016/0196-6553(91)90158-9